Building a Better Future: Bristol Myers Squibb 2023 ESG Report

NORTHAMPTON, MA / ACCESSWIRE / April 11, 2024 / Bristol Myers Squibb Company:

At Bristol Myers Squibb, our vision is to transform patients' lives through science

Originally published on Bristol Myers Squibb News & Perspectives

Since 1887, BMS has enabled positive change for patients around the world, and I am honored to continue this legacy as Board Chair and CEO. Our obligation to advance this legacy is profound. It calls for us to honor and uphold the values and principles that are the cornerstone of our past successes as we write the next chapter in BMS' history.

As we navigate an increasingly complex global landscape, our cohesive strategy, inclusive of our ESG performance, has never been more important. That's why, in 2023, we engaged a number of stakeholders, including patient advocacy partners, shareholders, suppliers, employees, multinational organizations and our Board to understand their views on ESG topics most important to our business and to society. Based on these insights, we evolved our ESG strategy to focus primarily on advancing patient health around the world and fostering a high-performing, inclusive workforce while expanding the boundaries of science and doing our part to reduce environmental impact.

Advancing patient health around the world

Patients, regardless of where they live, still encounter challenges to accessing medicines and adequate healthcare services. We believe in long-term sustainable solutions to address health inequities globally, and we are allocating specific resources and developing new pathways and models to expand access to patients in low- and middle-income countries (LMICs).

To enable this strategy, we are embedding access considerations as a core tenet across our business, fundamentally changing the way we operate. Our approach ranges from raising awareness about the social burden of medical conditions, to obtaining broader public reimbursement that reflects the value of our innovative medicines or providing copay assistance
to reduce the patient's out-of-pocket burden.

In LMICs, for example, we are developing tailored programs to help improve access to our innovative portfolio. Through new pathways we have made access possible to 12 transformative products for patients across 80+ LMICs. Of these, more than 40 are low-income countries receiving products at not-for-profit pricing, or at adjusted pricing that accounts for factors related to ability and willingness to pay. Additionally, we have forged global policy partnerships to help strengthen healthcare systems to better address local needs with the goal of delivering sustainable impacts for patients and communities.

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 46,86$, was eine Steigerung von +5,00% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

Morgan Stanley

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer